MGRX Valuation

Mangoceuticals Inc

Add to Watchlist

Advanced Chart

2.210

-0.03(-1.339%)1D

Overview
Forecast
Valuation
Earnings

MGRX Relative Valuation

MGRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MGRX is overvalued; if below, it's undervalued.

Historical Valuation

Mangoceuticals Inc (MGRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Mangoceuticals Inc (MGRX) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：2.22

Fair

0.00

Trailing

Forward

0.00

EV/EBITDA

Mangoceuticals Inc. (MGRX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

0.00

EV/EBIT

Mangoceuticals Inc. (MGRX) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBIT of 0.00 falls within the Strongly Undervalued range.

0.00

Mangoceuticals Inc. (MGRX) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

0.00

P/OCF

Mangoceuticals Inc. (MGRX) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.

0.00

P/FCF

Mangoceuticals Inc. (MGRX) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

Mangoceuticals Inc (MGRX) has a current Price-to-Book (P/B) ratio of 1.24. Compared to its 3-year average P/B ratio of 2.95 , the current P/B ratio is approximately -58.06% higher. Relative to its 5-year average P/B ratio of 2.95, the current P/B ratio is about -58.06% higher. Mangoceuticals Inc (MGRX) has a Forward Free Cash Flow (FCF) yield of approximately -23.43%. Compared to its 3-year average FCF yield of -59.63%, the current FCF yield is approximately -60.70% lower. Relative to its 5-year average FCF yield of -59.63% , the current FCF yield is about -60.70% lower.

1.24

P/B

Median3y

2.95

Median5y

2.95

-23.43

FCF Yield

Median3y

-59.63

Median5y

-59.63

Competitors Valuation Multiple

The average P/S ratio for MGRX's competitors is 16.29, providing a benchmark for relative valuation. Mangoceuticals Inc Corp (MGRX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of 3.03%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Neuphoria Therapeutics Inc

Neurosense Therapeutics Ltd

Allarity Therapeutics Inc

Loss

23.39M

Performance Decomposition

Market capitalization of MGRX decreased by 31.81% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -1.47K to -3.22K.

The secondary factor is the Revenue Growth, contributed 3.03%to the performance.

Overall, the performance of MGRX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

3.03%

163.16K → 168.11K

Revenue Growth

119.82%

-1.47K → -3.22K

Margin Expansion

-154.66%

1.31 → -0.71

P/E Change

-31.81%